Decentralized Trial Technology Insights
-
The 3 Stages Of Decentralized Trial Maturity
2/1/2023
Decentralized clinical trials (DCTs) offer clear benefits to patients and the overall success of the trial, but it can be difficult to know how to address this challenge. This three-stage framework approach will enable you to assess your organization’s current clinical trial innovation maturity and build a plan from there.
-
The 5Vs Of Collecting Clinical Data
1/26/2023
Not all data is created equal. Our data strategies need to be commensurate with the risks, complexity, and value of the data collected. If the true value of data is to be realized, it must be collected and captured in accordance with the five “V” dimensions: volume, variety, velocity, veracity, and value.
-
How BMS Uses AI To Improve Study Design And Reduce Costs
1/19/2023
In 2022, Bristol Myers Squibb (BMS) announced plans to work with AI developer Owkin to design and optimize cardiovascular drug trials. The partnership will allow BMS to use machine learning to enhance clinical trial design and execution.
-
Clinical Sites Are Optimistic, Despite Growing Challenges
1/17/2023
The last few years have not been easy for sites involved with conducting clinical research. The onset of the pandemic in 2020 created numerous challenges, including the implementation of new technologies and operating models, the leveraging of remote staff, and virtual facilities. Despite the ongoing challenges, global sites remain optimistic about the future of clinical trials.
-
How Can Clinical Research Better Navigate Healthcare Deserts?
1/17/2023
Large swaths of the U.S. remain healthcare deserts, where access to clinical sites, pharmacies, and hospitals is limited. This contributes to underrepresentation in clinical research. What are the roles of technology and community outreach, and what are some current industry efforts to address it?
-
The Long-Term Impact Of COVID-19 On Clinical Trials: Part 1
1/11/2023
Pandemics provide a massive pressure-test of healthcare systems, allowing us to isolate what works well and what merits improvement. The COVID-19 pandemic is going to create a “new normal” regarding resetting the equilibrium in a variety of policies, procedures, and processes. In Part 1, we examine five factors that more directly impact the clinical trial process and patients.
-
Two Straightforward Ways To Improve DE&I In Clinical Trials
12/27/2022
We don’t have to wait for federal guidance, additional DHT, or new innovations. We have the tools to begin to address the lack of trust and limited data and incorporate them into diversity plans for clinical trials today. Here's how.
-
How One Pharma Company Is Embracing Digital Technologies
12/21/2022
The increased demand for hybrid and decentralized approaches to clinical trials has increased the use of digital devices and other tools that will make studies more patient centric. Sanofi is one of the companies leading the way in getting devices into the hands of patients.
-
4 Essential Drivers In Clinical Development For Emerging Biotechs
12/21/2022
Enrollment, enrollment, enrollment has been the sponsor’s classic mantra for achieving success in a clinical trial. Rather, we should replace this notion with four equally essential building blocks: 1) the selection of the right CRO, 2) the identification of study sites, 3) the engagement of sites, and 4) the enrollment of patients.
-
The Future Of TransCelerate: Clinical Trial Modernization
12/19/2022
In January 2023, Janice Chang will take over as the head of industry consortia non-profit organization TransCelerate. Chang has been involved with TransCelerate since it was just a concept, and notes the time spent in the group since its launch has been an amazing journey.